#2627810
ag cur béim ar an bhfíoras, in ainneoin obair chrua na Gníomhaireachta in 2020, go raibh paindéim COVID-19 ina dhúshlán don bhonneagar slándála sláinte poiblí a bhí ann cheana, agus á chur i bhfios go láidir gur gá cumais na Gníomhaireachta a neartú chun a hathléimneacht agus a héifeachtacht a fheabhsú le linn tréimhsí éigeandála; á chur i bhfáth go n-éilítear freisin leis an gComhaontú Glas don Eoraip go ndéanfaidh an Ghníomhaireacht iarrachtaí breise, ar iarrachtaí iad a thugann údar le hacmhainní a leathnú; á chur in iúl gur díol sásaimh di go ndearnadh bearta chun an bonneagar slándála sláinte poiblí san Aontas a athdhearadh, lena n-áirítear trí Chlár EU4Health a bunaíodh le Rialachán (AE) 2021/522 ó Pharlaimint na hEorpa agus ón gComhairle, trí Rialachán (AE) 2022/123 ó Pharlaimint na hEorpa agus ón gComhairle agus tríd an teachtaireacht ón gCoimisiún an 25 Samhain 2020 dar teideal “Straitéis Chógaisíochta don Eoraip”; á iarraidh ar an gCúirt cur lena hiniúchadh don bhliain airgeadais 2021 maidir le feidhmiú na Gníomhaireachta laistigh den chomhthéacs institiúideach coigeartaithe; á iarraidh ar an gCúirt tuilleadh eolais a thabhairt i dtaobh an bhfuil, laistigh den socrú institiúideach coigeartaithe, dóthain acmhainní ag an nGníomhaireacht chun a sainordú leathnaithe a chur chun feidhme go héifeachtach;
Emphasises the fact that, despite the Agency’s hard work in 2020, the COVID-19 pandemic challenged the existing public health security infrastructure, and underlines the need to strengthen the capabilities of the Agency so as to improve its resilience and effectiveness during periods of emergency; stresses that the European Green Deal also requires additional efforts from the Agency, which justify an expansion of resources; welcomes the fact that steps have been taken to redesign the public health security infrastructure in the Union, including via the EU4Health Programme established by Regulation (EU) 2021/522 of the European Parliament and of the Council, via Regulation (EU) 2022/123 of the European Parliament and of the Council and via the communication of the Commission of 25 November 2020 entitled ‘Pharmaceutical Strategy for Europe’; calls upon the Court to expand in its audit for the 2021 financial year on the functioning of the Agency within the adjusted institutional context; calls upon the Court to expand on whether within the adjusted institutional setting, the Agency has enough resources to implement its expanded mandate effectively;